Darzalex (daratumumab) is an antibody pharmaceutical. Daratumumab was first approved as Darzalex on 2015-11-16. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
|Drug Class||Monoclonal antibodies|